U.S. Markets closed

Cara Therapeutics Posts 2018 Revenue 15X over 2017, Questions, Catalysts, and Hurdles Every Marijuana Stock Investor Should be Considering

NEW YORK, NY / ACCESSWIRE / April 11, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors.

Traders News Source has created a comprehensive report on the current state of the cannabis market, including an outlook on where the industry may be headed in 2019. Our report discussed the drivers behind the explosive industry growth and the legal issues and hurdles to come in the near term. This report is a must read for investors in cannabis stocks.

Read our comprehensive report on the cannabis/hemp industry here READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/cara-therapeutics/

Cara's lead candidate, Korsuva, an intravenous formulation is currently in a phase 3 clinical trial for treating pruritus (itching) in patients with chronic kidney disease who are on dialysis, while its oral formulation is in a phase 2 trial for the same indication in patients who aren't on dialysis. The company expects to announce the results from both studies this year.

Read our comprehensive report on the cannabis/hemp industry here READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/cara-therapeutics/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source



View source version on accesswire.com:
https://www.accesswire.com/541568/Cara-Therapeutics-Posts-2018-Revenue-15X-over-2017-Questions-Catalysts-and-Hurdles-Every-Marijuana-Stock-Investor-Should-be-Considering